{"database":"GEO","file_versions":[{"headers":{"Content-Type":["application/json"]},"body":{"files":{"Other":["ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE313nnn/GSE313916/"]},"type":"primary"},"statusCode":"OK","statusCodeValue":200}],"scores":null,"additional":{"omics_type":["Transcriptomics"],"species":["Homo sapiens"],"gds_type":["Expression profiling by high throughput sequencing"],"full_dataset_link":["https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE313916"],"repository":["GEO"],"entry_type":["GSE"],"additional_accession":[]},"is_claimable":false,"name":"Mechanisms of drug sensitivity for Low-Grade Serous Ovarian Carcinoma","description":"Quantitative high-throughput 2D drug screening (n=3436 compounds) was conducted across 12 patient-derived LGSOC cell lines representing MAPK-mutant and no-specific-molecular-profile (NSMP) subtypes, and a immortalised normal ovarian line (IOSE-523) as toxicity control. Hits were prioritised for synergy testing (29 combinations) with 6 anchor drugs and validated in 2D and 3D spheroid models. Mechanistic studies to elucidate mechanisms of drug sensitivity and resistance to drug classes was conducted via MAC-Seq transcriptomics (multiplexed analysis of cells, high-throughput RNA seq).","dates":{"publication":"2026/05/27"},"accession":"GSE313916","cross_references":{"GSM":["GSM9377766","GSM9377767","GSM9377764","GSM9377765"],"GPL":["18573"],"GSE":["313916"],"taxon":["Homo sapiens"],"PMID":["[42177640]"]}}